Regulation of the inducible nitric oxide synthase and sodium pump in type 1 diabetes

被引:10
|
作者
Zakula, Zorica
Koricanac, Goran
Putnikovic, Biljana
Markovic, Ljiljana
Isenovic, Esma R. [1 ]
机构
[1] Inst Vinca, Lab Mol Genet & Radiobiol, Belgrade 11000, Serbia
[2] Inst Vinca, Lab Mol Biol & Endocrinol, Belgrade 11000, Serbia
[3] Clin Ctr Zemun, Dept Cardiol, Belgrade 11000, Serbia
关键词
D O I
10.1016/j.mehy.2006.11.045
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Insulin-like growth factor-1 (IGF-1) is a hormone and growth factor closely related to insulin. The autocrine/paracrine actions of IGF-1 involve activation of inducible nitric oxide synthase (iNOS) and the Na+, K+-ATPase sodium pump in cardiovascular tissues. Data from literature indicate that iNOS is expressed in vascular smooth muscle cells (VSMC) and that IGF- 1 -induced release of NO is both rapid and delayed. We hypothesize that impaired IGF-1 -induced sodium pump activity/ expression in rats with type 1 diabetes is related to activation of phosphatidytinositol 3 kinase (PI3K)/cytosolic phospholipase 2 (cPLA(2))/protein kinase B (Akt) signaling, and that IGF-1 prevents acute and chronic dysfunction of iNOS and sodium pump activity in a chemically induced model of type 1 diabetes, the streptozotocin -treated rat heart (STZ). Understanding how iNOS and sodium pump activity are regulated by IGF-1 activation of the PI3K/cPLA(2)/Akt cascade should provide novel and fundamental knowledge regarding the regulatory actions of IGF-1 in promoting vasodilation. Since insulin resistance is currently a major focus of research, the use of IGF-1 to improve insulin resistance and glucose metabolism has opened a new arena for treatment of comorbid conditions. Future investigations should now focus on mechanisms of action of IGF-1 and its clinical applicability. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:302 / 306
页数:5
相关论文
共 50 条
  • [1] Linkage of the human inducible nitric oxide synthase gene to type 1 diabetes
    Johannesen, J
    Pie, A
    Pociot, F
    Kristiansen, OP
    Karlsen, AE
    Nerup, J
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (06): : 2792 - 2796
  • [2] Regulation of the expression of inducible nitric oxide synthase
    Kleinert, H
    Pautz, A
    Linker, K
    Schwarz, PM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 500 (1-3) : 255 - 266
  • [3] The regulation of inducible nitric oxide synthase by noradrenaline
    Feinstein, DL
    Gavrilyuk, V
    Dello Russo, C
    Galea, E
    GLIA, 2003, : 2 - 2
  • [4] Regulation of the expression of inducible nitric oxide synthase
    Pautz, Andrea
    Art, Julia
    Hahn, Susanne
    Nowag, Sebastian
    Voss, Cornelia
    Kleinert, Hartmut
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2010, 23 (02): : 75 - 93
  • [5] Regulation of the expression of inducible nitric oxide synthase
    Kleinert, H
    Schwarz, PM
    Förstermann, U
    BIOLOGICAL CHEMISTRY, 2003, 384 (10-11) : 1343 - 1364
  • [6] Regulation of inducible nitric oxide synthase in the retina
    Goureau, O
    Faure, V
    De Kozak, Y
    Behar-Cohen, F
    Dighiero, P
    Courtois, Y
    NITRIC OXIDE IN THE EYE, 2000, : 135 - 142
  • [7] Inhibition of inducible nitric oxide synthase improved erectile dysfunction in rats with type 1 diabetes
    Liu, Li
    Wang, Xiao
    Liu, Kang
    Kang, Jiaqi
    Wang, Shangren
    Song, Yuxuan
    Zhou, Kechong
    Yi, Lu
    Liu, Xiaoqiang
    ANDROLOGIA, 2021, 53 (08)
  • [8] Polymorphisms in the inducible nitric oxide synthase (iNOS) gene are not associated with nephropathy in type 1 diabetes
    Makita, Y
    Pezzolesi, M
    Warram, JH
    Krolewski, AS
    DIABETES, 2000, 49 : A157 - A158
  • [9] Regulation of the Expression of Inducible Nitric Oxide Synthase by Prostanoids
    Yamada, Takehiro
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2009, 129 (10): : 1211 - 1214
  • [10] Inducible nitric oxide synthase in the liver: Regulation and function
    Taylor, BS
    Alarcon, LH
    Billiar, TR
    BIOCHEMISTRY-MOSCOW, 1998, 63 (07) : 766 - 781